An Intercompany Perspective on Compatibility and In-use Stability Studies to Enable Administration Of Biopharmaceutical Drug Products

被引:13
作者
Kamen, Douglas E. [1 ]
Crotts, George [2 ]
Narasimhan, Chakravarthy [3 ]
Hu, Qingyan [1 ]
Bhargava, Adithi C. [4 ]
Muthurania, Kevin [5 ]
Burton, Lori [6 ]
Gbormittah, Francisca O. [7 ]
Mathews, Ligi
Mills, Brittney [8 ]
Hodge, Tamara [9 ]
Saluja, Sonal [10 ]
Singh, Shubhadra N. [2 ]
Tabish, Tanvir [11 ]
Wu, Yongmei [6 ]
Stokes, Elaine S. E. [12 ]
机构
[1] Regeneron Pharmaceut Inc, Formulat Dev, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA
[2] GlaxoSmithKline R&D, Biopharmaceut Prod Sci, Collegeville, PA 19426 USA
[3] Merck & Co Inc, Biol & Vaccines Dev, 2000 Galloping Hill Rd, Kenilworth, NJ 07033 USA
[4] Genentech Inc, Pharmaceut Dev, 1 DNA Way, South San Francisco, CA 94080 USA
[5] Janssen Res & Dev, Biotherapeut Drug Prod Dev, 200 Great Valley Pkwy, Malvern, PA 19355 USA
[6] Bristol Myers Squibb, Drug Prod Dev, One Squibb Dr, New Brunswick, NJ 08903 USA
[7] Alkermes Inc, 852 Winter St,142, Waltham, MA 02451 USA
[8] Abbvie, NBE Dev, 1N Waukegan Rd, N Chicago, IL 60064 USA
[9] Pfizer Inc, BioTherapeut PharmSci, 1 Burtt Rd, Andover, MA 01810 USA
[10] 225 Binney St, Cambridge, MA 02142 USA
[11] Takeda Pharmaceut, Industriestr 72, A-1221 Vienna, Austria
[12] BioPhorum, Gridiron Bldg, 1 Pancras Sq, London N1C 4AG, England
关键词
MONOCLONAL-ANTIBODY; FORMULATION; DILUTION;
D O I
10.1016/j.xphs.2021.09.043
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
In-use stability and compatibility studies are often used in biotherapeutic development to assess stability and compatibility of biologic drugs with diluents and/or administration components at relevant conditions for the target route of administration (commonly intravenous, subcutaneous or intramuscular), to assure that patient safety and product efficacy are maintained during clinical use. To gain an understanding of current industry approaches for in-use stability and compatibility studies, the Formulation Workstream of the BioPhorum Development Group (BPDG), an industry-wide consortium, conducted an inter-company collaboration exercise, which included five bench-marking surveys around in-use stability and compatibility studies of biologic drugs. The results of this industry collaboration provide insights into the practicalities of these studies and how they are being used to support administration of biologics from early clinical programs to marketed products. The surveys queried topics including regulatory strategies and feedback; clinical in-use formulation, patient and site considerations; clinical blinding, masking and placebo approaches; study setup, execution and reporting; and clinical in-use stability and compatibility testing to provide a comprehensive picture of the range of common industry practices. This paper discusses the survey results and presents various approaches which can be used to guide the strategy and design of an in-use stability and compatibility program based on clinical and biomolecule needs. (c) 2021 Dr. Elaine SE Stokes. Published by Elsevier Inc. on behalf of American Pharmacists Association. All rights reserved.
引用
收藏
页码:1092 / 1103
页数:12
相关论文
共 27 条
  • [1] Statistics Notes - Blinding in clinical trials and other studies
    Day, SJ
    Altman, DG
    [J]. BRITISH MEDICAL JOURNAL, 2000, 321 (7259) : 504 - 504
  • [2] Next generation immunotherapeutics-honing the magic bullet
    Enever, Carrie
    Batuwangala, Thil
    Plummer, Chris
    Sepp, Armin
    [J]. CURRENT OPINION IN BIOTECHNOLOGY, 2009, 20 (04) : 405 - 411
  • [3] European Medicines Agency, 2017, GUID REQ CHEM PHARM
  • [4] Food and Drug Administration, SAF ASS DI2 ETH DEHP
  • [5] Food and Drug Administration, 2003, GUID IND Q1AR2 STAB
  • [6] Gill Harvinder S, 2007, J Diabetes Sci Technol, V1, P725
  • [7] Capacity of Infusion Lines for Insulin Adsorption: Effect of Flow Rate on Total Adsorption
    Knopp, Jennifer L.
    Bishop, Kaia
    Lerios, Theodore
    Chase, J. Geoffrey
    [J]. JOURNAL OF DIABETES SCIENCE AND TECHNOLOGY, 2021, 15 (01): : 109 - 120
  • [8] Formulation and Administration of Biological Medicinal Products"
    Kraemer, Irene
    Thiesen, Judith
    Astier, Alain
    [J]. PHARMACEUTICAL RESEARCH, 2020, 37 (08)
  • [9] Compatibility, physical stability, and characterization of an IgG4 monoclonal antibody after dilution into different intravenous administration bags
    Kumru, Ozan S.
    Liu, Jun
    Ji, Junyan A.
    Cheng, Wilson
    Wang, Y. John
    Wang, Tingting
    Joshi, Sangeeta B.
    Middaugh, C. Russell
    Volkin, David B.
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 2012, 101 (10) : 3636 - 3650
  • [10] Pain perception after subcutaneous injections of media containing different buffers
    Laursen, T
    Hansen, B
    Fisker, S
    [J]. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2006, 98 (02) : 218 - 221